면책 고지: 이 사이트는 FDA, ClinicalTrials.gov, PubMed, SEC EDGAR 등 공식 공개 데이터를 일반 참고용으로 집계하며, 의학적 조언, 진단, 치료 권고 또는 투자 조언이 아닙니다.

임상시험

Radioembolization in Elderly/ Fragile Patients With mCRC

NCT: NCT05092880 · TERMINATED

NCT IDNCT05092880
상태TERMINATED
시작일2022-06-01
완료2025-09-01
SponsorUMC Utrecht (OTHER)
First posted
Last updated

간략 요약

Radioembolization (RE) is a minimally invasive treatment with administration of radioactive microspheres into the hepatic artery via a microcatheter. Since tumors are preferentially supplied by the hepatic artery, most microspheres get trapped in the tumor. RE has been shown a feasible and safe procedure for the treatment of unresectable CRC liver metastases. These data compare favourably with the toxicity data of capecitabine plus bevacizumab, but this should be validated in a prospective study. The proposed study investigates the efficacy of RE as an alternative, better tolerated and more cost-effective treatment option in elderly or frail patients compared to chronic systemic treatment with comparable progression-free survival.

공식 출처

ClinicalTrials.gov에서 보기 →

데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.

↑